Agrigenomics Market by Product Type (Consumables, Instruments, Software And Services), Technology (Bioinformatics, DNA Sequencing, Gene Editing), Application, End User - Global Forecast 2025-2032
Description
The Agrigenomics Market was valued at USD 15.16 billion in 2024 and is projected to grow to USD 16.79 billion in 2025, with a CAGR of 10.58%, reaching USD 33.92 billion by 2032.
Concise strategic framing of agrigenomics innovations, operational drivers, and the technological building blocks reshaping agricultural research and commercialization
Agrigenomics is transforming agriculture by integrating advanced molecular tools with data-driven decision making to optimize crop and livestock performance. Recent advances in sequencing, gene editing, and bioinformatics have converged to enable more precise trait selection, accelerated breeding cycles, and improved diagnostic capabilities. These technical foundations are enabling researchers and commercial teams to address long-standing challenges related to yield stability, disease resistance, and nutritional quality while adapting to evolving regulatory and trade environments.
This introduction outlines the strategic context for leaders evaluating investments in agrigenomics capabilities. It highlights the technological building blocks, the shifting interplay between translational research and commercial deployment, and the emergent need for integrated platforms that combine consumables, instruments, and software and services. Throughout, emphasis is placed on actionable intelligence that informs R&D prioritization, partnership models, and operational readiness for scaling genomic interventions across agricultural value chains.
Pervasive technological convergence, collaborative workflows, and platform-based commercial models that are rapidly redefining agrigenomics innovation and adoption
The agrigenomics landscape is undergoing transformative shifts driven by accelerating technology maturity, greater data integration, and evolving stakeholder expectations. Rapid improvements in DNA sequencing throughput and cost efficiency are enabling broader adoption of genomic selection and diagnostic applications across both crops and livestock. Simultaneously, gene editing platforms have moved from proof-of-concept toward field-relevant tools that can deliver trait improvements with unprecedented precision and speed.
Beyond technology, transformation is occurring in how organizations operate. Cross-disciplinary collaboration among breeders, molecular biologists, and data scientists is becoming essential, and there is growing emphasis on end-to-end workflows that link sample collection, sequencing, data analysis, and actionable insights. Commercial models are also shifting from product-centric offerings to platform and service-oriented propositions, with increased demand for bioinformatics pipelines, managed services, and consulting to interpret complex multi-omic datasets. These shifts are influencing investment priorities, talent acquisition, and the types of partnerships that will define competitive advantage in the coming years.
Analysis of the cascading operational, procurement, and collaboration effects arising from new United States tariff measures introduced in 2025
The introduction of new tariff measures by the United States in 2025 has introduced layered effects across the agrigenomics value chain, affecting inputs, instrument flows, and cross-border service delivery. Tariffs on certain laboratory equipment and reagents have the practical effect of increasing landed costs for research institutes and commercial laboratories, prompting procurement teams to reassess supplier portfolios and inventory strategies. This cost pressure is likely to accelerate consolidation among buyers and encourage longer-term purchasing agreements to stabilize budgets and supply lines.
Trade barriers are also influencing supply chain design and R&D collaboration structures. Institutions that previously relied on rapid international reagent shipments or offshore instrument servicing are exploring local stocking strategies, expanded regional service contracts, and strategic partnerships with domestic manufacturers. At the same time, tariffs can induce geographic shifts in where certain value-added activities occur, encouraging relocation of some processing steps to tariff-favored jurisdictions or triggering investments in in-country manufacturing capabilities. While these adjustments seek to preserve research continuity, they also demand increased attention to regulatory compliance, logistics planning, and scenario-based financial modeling to mitigate the operational impact of tariff volatility.
Detailed segmentation-driven insights that delineate differentiated adoption pathways across product types, technologies, applications, and end users to guide precise market approaches
Segment-level dynamics reveal differentiated opportunities and barriers across product types, technologies, applications, and end users that require distinct commercialization strategies. In terms of product type, consumables are driven by recurring demand for kits and reagents used in routine genotyping, sequencing, and assays, while instruments encompass capital purchases such as microarray scanners, PCR machines, and sequencers that follow longer procurement cycles and require service and validation. Software and services are increasingly critical, spanning bioinformatics software that supports data analysis and database management as well as consulting services that translate complex datasets into actionable breeding or diagnostic decisions.
Technology segmentation highlights nuanced adoption pathways. Bioinformatics is segmented into data analysis software and database management, enabling both interpretation and secure stewardship of ever-larger genomic datasets. DNA sequencing divides into next-generation sequencing and Sanger sequencing, each serving different throughput and resolution needs. Gene editing includes CRISPR and TALEN modalities, which vary by precision and regulatory considerations. Genotyping modalities split between microarray-based approaches and PCR-based methods, reflecting trade-offs between cost, throughput, and analytical resolution. Transcriptomics continues to bifurcate into QPCR arrays for targeted expression profiling and RNA sequencing for broader transcriptome characterization, supporting both functional discovery and diagnostic applications.
Application-driven insights indicate that animal health initiatives rely heavily on diagnostics and genotyping to manage herd health and breeding, crop improvement leverages sequencing and gene editing for trait development, disease diagnostics demand high-sensitivity assays and rapid turnarounds, and personalized nutrition is an emerging area that connects genomic information to dietary optimization. End users span agricultural biotechnology companies focused on product development, agricultural research institutes pursuing foundational and translational studies, government and research organizations involved in policy-driven programs and surveillance, and seed companies that integrate genomic tools into breeding pipelines. Each end user has distinct purchasing behaviors, validation requirements, and timelines for adoption, which should inform tailored go-to-market approaches and service models.
Comparative regional dynamics and strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, regulation, and commercialization
Regional dynamics vary considerably and create differentiated priorities for investment, regulatory engagement, and partnership formation. In the Americas, established private sector ecosystems and advanced research infrastructure favor rapid deployment of sequencing and gene-editing applications, while evolving regulatory frameworks and trade policy shifts create a need for adaptive market-entry strategies and supply chain resilience. Stakeholders in this region are focused on scaling diagnostic services and integrating genomics into large commercial breeding programs.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory rigor, diverse climatic conditions, and varying research capacities necessitate region-specific engagement models. In parts of Europe, stringent regulatory oversight shapes adoption timelines and requires robust safety and traceability evidence, whereas markets across the Middle East & Africa may prioritize capacity building, technology transfer, and public-private collaborations to deploy foundational genomic tools. The Asia-Pacific region is characterized by rapid adoption in major agricultural economies, significant investment in local instrument manufacturing, and a high appetite for scalable bioinformatics solutions to manage large national breeding programs. Each region’s distinctive policy settings and infrastructure readiness inform both risk assessment and opportunity prioritization for commercial programs.
Competitive behaviors and corporate strategies focused on platform integration, recurring revenue models, and collaborative partnerships to accelerate agrigenomics commercialization
Companies operating in the agrigenomics ecosystem are differentiating through vertical integration, platform development, and collaborative alliances that combine laboratory capabilities with data analytics and field-scale validation. Leading commercial strategies emphasize expanding recurring revenue streams via consumables and software subscriptions, while also investing in instrument service networks and regional distribution to shorten lead times. Strategic partnerships between technology vendors, contract research organizations, and breeding companies are increasingly common as firms seek to de-risk development pathways and accelerate access to application-specific expertise.
Innovation-focused organizations are allocating resources toward bioinformatics pipelines, robust data governance frameworks, and customer-centric service offerings that help end users interpret complex genomic datasets. Meanwhile, some companies are pursuing modular product roadmaps that allow rapid adjustment to regulatory developments and tariff-driven supply chain constraints. These competitive moves create opportunities for specialist providers that can offer validated assays, managed sequencing services, or targeted consulting expertise to support adoption in regulated and emerging markets alike.
Action-oriented strategic imperatives for leaders to build integrated platforms, resilient supply chains, and client-focused services that accelerate adoption and value capture
Industry leaders should prioritize three interrelated initiatives to capture near-term value and build durable competitive advantage. First, strengthen integrated platform capabilities that combine validated consumables, reliable instrument servicing, and intuitive bioinformatics to reduce friction in adoption and deliver faster time-to-insight for customers. Prioritizing interoperability and standardized data formats will encourage adoption by lowering the cost of integration into existing workflows and facilitating multi-party collaborations.
Second, build resilient supply chains and regional service footprints to mitigate tariff and logistics risks while improving responsiveness to localized demand. This includes diversified sourcing strategies, strategic stocking agreements, and targeted investments in regional calibration and maintenance centers. Third, expand client-centric services that translate genomic outputs into actionable decisions for breeders, veterinarians, and nutritionists. Investing in consulting capabilities and outcome-based service models can create higher-margin revenue streams while enhancing customer retention. Collectively, these steps position organizations to respond to regulatory shifts and capture long-term demand across diverse end users and geographies.
Robust mixed-methods research design combining primary stakeholder engagement, secondary technical validation, and iterative triangulation to ensure actionable insights
The research approach combines primary stakeholder engagement with rigorous secondary validation to ensure findings reflect operational realities and near-term strategic considerations. Primary inputs included structured interviews and workshops with practitioners across research institutes, seed companies, agricultural biotechnology firms, and government research bodies to capture firsthand perspectives on technology adoption, procurement priorities, and regulatory concerns. These qualitative insights were complemented by case analyses of recent deployments and public disclosures to triangulate observed behaviors and strategic initiatives.
Secondary research drew on peer-reviewed literature, regulatory documents, technical application notes, and industry technical standards to validate methodological assumptions and technology characterizations. Data were synthesized through iterative triangulation to reconcile divergent viewpoints and isolate robust trends. The methodology also included sensitivity checks and scenario planning to explore the operational implications of tariff changes and regional policy shifts. Limitations are acknowledged where proprietary commercial data were not accessible, and recommendations are presented with explicit caveats where adoption timelines depend on external regulatory or trade developments.
Concise synthesis of strategic priorities and capability areas that will determine who successfully translates agrigenomics innovation into scalable agricultural impact
In summary, agrigenomics is at an inflection point where technological progress, shifting commercial models, and evolving policy environments are collectively reshaping research and commercialization pathways. Stakeholders that align investments across integrated platforms, data analytics, and regional operational capabilities will be better positioned to convert scientific advances into scalable agricultural outcomes. Attention to supply chain resilience and adaptive procurement strategies will be essential in managing near-term disruptions and sustaining R&D momentum.
Decision-makers should prioritize selective capability building that complements existing strengths, while pursuing partnerships that accelerate access to niche expertise and regional distribution. By focusing on interoperability, validated workflows, and client-centric services, organizations can shorten the path from laboratory innovation to field impact and capture growing demand for genomic-enabled solutions across crops, livestock, and nutrition applications.
Please Note: PDF & Excel + Online Access - 1 Year
Concise strategic framing of agrigenomics innovations, operational drivers, and the technological building blocks reshaping agricultural research and commercialization
Agrigenomics is transforming agriculture by integrating advanced molecular tools with data-driven decision making to optimize crop and livestock performance. Recent advances in sequencing, gene editing, and bioinformatics have converged to enable more precise trait selection, accelerated breeding cycles, and improved diagnostic capabilities. These technical foundations are enabling researchers and commercial teams to address long-standing challenges related to yield stability, disease resistance, and nutritional quality while adapting to evolving regulatory and trade environments.
This introduction outlines the strategic context for leaders evaluating investments in agrigenomics capabilities. It highlights the technological building blocks, the shifting interplay between translational research and commercial deployment, and the emergent need for integrated platforms that combine consumables, instruments, and software and services. Throughout, emphasis is placed on actionable intelligence that informs R&D prioritization, partnership models, and operational readiness for scaling genomic interventions across agricultural value chains.
Pervasive technological convergence, collaborative workflows, and platform-based commercial models that are rapidly redefining agrigenomics innovation and adoption
The agrigenomics landscape is undergoing transformative shifts driven by accelerating technology maturity, greater data integration, and evolving stakeholder expectations. Rapid improvements in DNA sequencing throughput and cost efficiency are enabling broader adoption of genomic selection and diagnostic applications across both crops and livestock. Simultaneously, gene editing platforms have moved from proof-of-concept toward field-relevant tools that can deliver trait improvements with unprecedented precision and speed.
Beyond technology, transformation is occurring in how organizations operate. Cross-disciplinary collaboration among breeders, molecular biologists, and data scientists is becoming essential, and there is growing emphasis on end-to-end workflows that link sample collection, sequencing, data analysis, and actionable insights. Commercial models are also shifting from product-centric offerings to platform and service-oriented propositions, with increased demand for bioinformatics pipelines, managed services, and consulting to interpret complex multi-omic datasets. These shifts are influencing investment priorities, talent acquisition, and the types of partnerships that will define competitive advantage in the coming years.
Analysis of the cascading operational, procurement, and collaboration effects arising from new United States tariff measures introduced in 2025
The introduction of new tariff measures by the United States in 2025 has introduced layered effects across the agrigenomics value chain, affecting inputs, instrument flows, and cross-border service delivery. Tariffs on certain laboratory equipment and reagents have the practical effect of increasing landed costs for research institutes and commercial laboratories, prompting procurement teams to reassess supplier portfolios and inventory strategies. This cost pressure is likely to accelerate consolidation among buyers and encourage longer-term purchasing agreements to stabilize budgets and supply lines.
Trade barriers are also influencing supply chain design and R&D collaboration structures. Institutions that previously relied on rapid international reagent shipments or offshore instrument servicing are exploring local stocking strategies, expanded regional service contracts, and strategic partnerships with domestic manufacturers. At the same time, tariffs can induce geographic shifts in where certain value-added activities occur, encouraging relocation of some processing steps to tariff-favored jurisdictions or triggering investments in in-country manufacturing capabilities. While these adjustments seek to preserve research continuity, they also demand increased attention to regulatory compliance, logistics planning, and scenario-based financial modeling to mitigate the operational impact of tariff volatility.
Detailed segmentation-driven insights that delineate differentiated adoption pathways across product types, technologies, applications, and end users to guide precise market approaches
Segment-level dynamics reveal differentiated opportunities and barriers across product types, technologies, applications, and end users that require distinct commercialization strategies. In terms of product type, consumables are driven by recurring demand for kits and reagents used in routine genotyping, sequencing, and assays, while instruments encompass capital purchases such as microarray scanners, PCR machines, and sequencers that follow longer procurement cycles and require service and validation. Software and services are increasingly critical, spanning bioinformatics software that supports data analysis and database management as well as consulting services that translate complex datasets into actionable breeding or diagnostic decisions.
Technology segmentation highlights nuanced adoption pathways. Bioinformatics is segmented into data analysis software and database management, enabling both interpretation and secure stewardship of ever-larger genomic datasets. DNA sequencing divides into next-generation sequencing and Sanger sequencing, each serving different throughput and resolution needs. Gene editing includes CRISPR and TALEN modalities, which vary by precision and regulatory considerations. Genotyping modalities split between microarray-based approaches and PCR-based methods, reflecting trade-offs between cost, throughput, and analytical resolution. Transcriptomics continues to bifurcate into QPCR arrays for targeted expression profiling and RNA sequencing for broader transcriptome characterization, supporting both functional discovery and diagnostic applications.
Application-driven insights indicate that animal health initiatives rely heavily on diagnostics and genotyping to manage herd health and breeding, crop improvement leverages sequencing and gene editing for trait development, disease diagnostics demand high-sensitivity assays and rapid turnarounds, and personalized nutrition is an emerging area that connects genomic information to dietary optimization. End users span agricultural biotechnology companies focused on product development, agricultural research institutes pursuing foundational and translational studies, government and research organizations involved in policy-driven programs and surveillance, and seed companies that integrate genomic tools into breeding pipelines. Each end user has distinct purchasing behaviors, validation requirements, and timelines for adoption, which should inform tailored go-to-market approaches and service models.
Comparative regional dynamics and strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, regulation, and commercialization
Regional dynamics vary considerably and create differentiated priorities for investment, regulatory engagement, and partnership formation. In the Americas, established private sector ecosystems and advanced research infrastructure favor rapid deployment of sequencing and gene-editing applications, while evolving regulatory frameworks and trade policy shifts create a need for adaptive market-entry strategies and supply chain resilience. Stakeholders in this region are focused on scaling diagnostic services and integrating genomics into large commercial breeding programs.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory rigor, diverse climatic conditions, and varying research capacities necessitate region-specific engagement models. In parts of Europe, stringent regulatory oversight shapes adoption timelines and requires robust safety and traceability evidence, whereas markets across the Middle East & Africa may prioritize capacity building, technology transfer, and public-private collaborations to deploy foundational genomic tools. The Asia-Pacific region is characterized by rapid adoption in major agricultural economies, significant investment in local instrument manufacturing, and a high appetite for scalable bioinformatics solutions to manage large national breeding programs. Each region’s distinctive policy settings and infrastructure readiness inform both risk assessment and opportunity prioritization for commercial programs.
Competitive behaviors and corporate strategies focused on platform integration, recurring revenue models, and collaborative partnerships to accelerate agrigenomics commercialization
Companies operating in the agrigenomics ecosystem are differentiating through vertical integration, platform development, and collaborative alliances that combine laboratory capabilities with data analytics and field-scale validation. Leading commercial strategies emphasize expanding recurring revenue streams via consumables and software subscriptions, while also investing in instrument service networks and regional distribution to shorten lead times. Strategic partnerships between technology vendors, contract research organizations, and breeding companies are increasingly common as firms seek to de-risk development pathways and accelerate access to application-specific expertise.
Innovation-focused organizations are allocating resources toward bioinformatics pipelines, robust data governance frameworks, and customer-centric service offerings that help end users interpret complex genomic datasets. Meanwhile, some companies are pursuing modular product roadmaps that allow rapid adjustment to regulatory developments and tariff-driven supply chain constraints. These competitive moves create opportunities for specialist providers that can offer validated assays, managed sequencing services, or targeted consulting expertise to support adoption in regulated and emerging markets alike.
Action-oriented strategic imperatives for leaders to build integrated platforms, resilient supply chains, and client-focused services that accelerate adoption and value capture
Industry leaders should prioritize three interrelated initiatives to capture near-term value and build durable competitive advantage. First, strengthen integrated platform capabilities that combine validated consumables, reliable instrument servicing, and intuitive bioinformatics to reduce friction in adoption and deliver faster time-to-insight for customers. Prioritizing interoperability and standardized data formats will encourage adoption by lowering the cost of integration into existing workflows and facilitating multi-party collaborations.
Second, build resilient supply chains and regional service footprints to mitigate tariff and logistics risks while improving responsiveness to localized demand. This includes diversified sourcing strategies, strategic stocking agreements, and targeted investments in regional calibration and maintenance centers. Third, expand client-centric services that translate genomic outputs into actionable decisions for breeders, veterinarians, and nutritionists. Investing in consulting capabilities and outcome-based service models can create higher-margin revenue streams while enhancing customer retention. Collectively, these steps position organizations to respond to regulatory shifts and capture long-term demand across diverse end users and geographies.
Robust mixed-methods research design combining primary stakeholder engagement, secondary technical validation, and iterative triangulation to ensure actionable insights
The research approach combines primary stakeholder engagement with rigorous secondary validation to ensure findings reflect operational realities and near-term strategic considerations. Primary inputs included structured interviews and workshops with practitioners across research institutes, seed companies, agricultural biotechnology firms, and government research bodies to capture firsthand perspectives on technology adoption, procurement priorities, and regulatory concerns. These qualitative insights were complemented by case analyses of recent deployments and public disclosures to triangulate observed behaviors and strategic initiatives.
Secondary research drew on peer-reviewed literature, regulatory documents, technical application notes, and industry technical standards to validate methodological assumptions and technology characterizations. Data were synthesized through iterative triangulation to reconcile divergent viewpoints and isolate robust trends. The methodology also included sensitivity checks and scenario planning to explore the operational implications of tariff changes and regional policy shifts. Limitations are acknowledged where proprietary commercial data were not accessible, and recommendations are presented with explicit caveats where adoption timelines depend on external regulatory or trade developments.
Concise synthesis of strategic priorities and capability areas that will determine who successfully translates agrigenomics innovation into scalable agricultural impact
In summary, agrigenomics is at an inflection point where technological progress, shifting commercial models, and evolving policy environments are collectively reshaping research and commercialization pathways. Stakeholders that align investments across integrated platforms, data analytics, and regional operational capabilities will be better positioned to convert scientific advances into scalable agricultural outcomes. Attention to supply chain resilience and adaptive procurement strategies will be essential in managing near-term disruptions and sustaining R&D momentum.
Decision-makers should prioritize selective capability building that complements existing strengths, while pursuing partnerships that accelerate access to niche expertise and regional distribution. By focusing on interoperability, validated workflows, and client-centric services, organizations can shorten the path from laboratory innovation to field impact and capture growing demand for genomic-enabled solutions across crops, livestock, and nutrition applications.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of CRISPR-based gene editing to develop climate-resilient crop varieties resistant to drought and heat stress
- 5.2. Adoption of high-throughput sequencing platforms for rapid identification of disease resistance genes in commercial seeds
- 5.3. Deployment of AI-driven phenomics with genomic data to accelerate breeding cycles and predict trait performance under field conditions
- 5.4. Utilization of microbial consortia genomics to enhance soil health and nutrient uptake in precision agriculture systems
- 5.5. Implementation of genomic selection models leveraging polygenic risk scores for yield improvement across diverse environmental gradients
- 5.6. Expansion of gene drive technologies targeting pest populations to reduce reliance on chemical pesticides and boost crop protection
- 5.7. Collaboration between agribiotech companies and data analytics firms for blockchain-secured tracking of seed genetic pedigrees from lab to farm
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Agrigenomics Market, by Product Type
- 8.1. Consumables
- 8.1.1. Kits
- 8.1.2. Reagents
- 8.2. Instruments
- 8.2.1. Microarray Scanners
- 8.2.2. PCR Machines
- 8.2.3. Sequencers
- 8.3. Software And Services
- 8.3.1. Bioinformatics Software
- 8.3.2. Consulting Services
- 9. Agrigenomics Market, by Technology
- 9.1. Bioinformatics
- 9.1.1. Data Analysis Software
- 9.1.2. Database Management
- 9.2. DNA Sequencing
- 9.2.1. Next-Generation Sequencing
- 9.2.2. Sanger Sequencing
- 9.3. Gene Editing
- 9.3.1. CRISPR
- 9.3.2. TALEN
- 9.4. Genotyping
- 9.4.1. Microarray Based
- 9.4.2. PCR Based
- 9.5. Transcriptomics
- 9.5.1. QPCR Arrays
- 9.5.2. RNA Sequencing
- 10. Agrigenomics Market, by Application
- 10.1. Animal Health
- 10.2. Crop Improvement
- 10.3. Disease Diagnostics
- 10.4. Personalized Nutrition
- 11. Agrigenomics Market, by End User
- 11.1. Agricultural Biotechnology Companies
- 11.2. Agricultural Research Institutes
- 11.3. Government And Research Organizations
- 11.4. Seed Companies
- 12. Agrigenomics Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Agrigenomics Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Agrigenomics Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Agilent Technologies Inc
- 15.3.2. Bayer AG
- 15.3.3. BGI Group
- 15.3.4. Bio-Rad Laboratories Inc
- 15.3.5. Calyxt Inc
- 15.3.6. Cargill Inc
- 15.3.7. Corteva Agriscience
- 15.3.8. Eurofins Scientific SE
- 15.3.9. Evogene Ltd
- 15.3.10. F. Hoffmann-La Roche AG
- 15.3.11. Genus plc
- 15.3.12. Illumina Inc
- 15.3.13. Inari Agriculture Inc
- 15.3.14. KeyGene NV
- 15.3.15. KWS SAAT SE & Co KGaA
- 15.3.16. LGC Limited
- 15.3.17. Limagrain
- 15.3.18. Neogen Corporation
- 15.3.19. NRGene Ltd
- 15.3.20. Oxford Nanopore Technologies Ltd
- 15.3.21. Pacific Biosciences of California Inc
- 15.3.22. QIAGEN N.V.
- 15.3.23. Syngenta AG
- 15.3.24. Tecan Genomics Inc
- 15.3.25. Thermo Fisher Scientific Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
